NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY
Data(s) |
01/06/2010
|
---|---|
Identificador | |
Idioma(s) |
eng |
Direitos |
info:eu-repo/semantics/restrictedAccess |
Fonte |
O'Dwyer , E , Swords , R , Giles , F , LeCoutre , P , McMullin , M F , Langabeer , S , Padmanabhan , S , Kent , E , Parker , M , Moulton , B , Egan , K & Conneally , E 2010 , ' NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY ' HAEMATOLOGICA , vol 95 , pp. 340-340 . |
Tipo |
article |